Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition

Atara Biotherapeutics

12/08/2026 21:14

Overview
US T-cell immunotherapy developer's Q2 revenue beat analyst expectations, but fell sharply yr/yr
Company reported Q2 net loss and basic and diluted loss per share
Q2 costs and operating expenses declined 87% yr/yr after cost-reduction initiatives

Outlook
Operating expenses expected to decline significantly year-over-year due to cost-reduction initiatives
Company expects cash and investments to fund operations into mid-2027
Atara anticipates further regulatory update on tabelecleucel BLA resubmission later this quarter

Result Drivers
DEFERRED REVENUE RECOGNITION - Revenue fell mainly due to accelerated recognition of deferred revenue in 2025 after transition of development activities to Pierre Fabre Laboratories
COST REDUCTION INITIATIVES - Significant decline in operating expenses attributed to cost-reduction measures implemented in 2025 and first half of 2026

Company press release: ID:nBw6kz6Bpa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Commercialization Revenue
Beat
$630,000
$366,670 (3 Analysts)
Q2 Loss Per Share
 
$0.32
 
Q2 Net Loss
 
$4.83 mln
 
Q2 Operating Income
 
-$4.72 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Atara Biotherapeutics, Inc. is $13.00, about 45.4% above its August 11 closing price of $8.94

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount
Aug 11 - Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)